{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":34,"n_cols":5,"rows_kept":34,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[13,2,13,3],[13,4,13,5],[14,2,14,3],[14,4,14,5],[15,2,15,3],[15,4,15,5],[16,2,16,3],[18,2,18,3],[19,2,19,3],[20,2,20,3],[21,2,21,3],[27,2,27,3],[28,2,28,3],[31,2,31,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNISA996303449803316"]
[null,null,"Autore",null,"SALVI, Antonio <1969-    >"]
[null,null,"Titolo",null,"Gli  strumenti finanziari derivati nella gestione delle aziende : profili economico-aziendali e di corporate financial risk management / di Antonio Salvi e Alberto Tron"]
[null,null,"Pubbl/distr/stampa",null,"Milano : Giuffrè Francis Lefebvre, 2019"]
[null,null,"ISBN",null,"978-88-288-0808-4"]
[null,null,"Descrizione fisica",null,"XIX, 272 p. ; 24 cm"]
[null,null,"Collana",null,"Collana dell'Università LUM Jean Monnet , Serie economica ; 1"]
[null,null,"Disciplina",null,"658.155"]
[null,null,"Soggetti",null,"Finanza aziendale - Rischi - Gestione - Impiego [dei] Derivati <Strumenti finanziari>"]
[null,null,"Collocazione",null,"658.155 STR 2"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,"2.","Record Nr.",null,"UNINA9910821772403321"]
[null,null,"Autore",null,"Robinson James C (James Claude), <1953->"]
[null,null,"Titolo",null,"Purchasing medical innovation : the right technology, for the right patient, at the right price / / James C. Robinson"]
[null,null,"Pubbl/distr/stampa",null,"Oakland, California : , : University of California Press, , 2015"]
[{"$nulls":4},"©2015"]
[null,null,"ISBN",null,"0-520-96081-5"]
[null,null,"Descrizione fisica",null,"1 online resource (183 p.)"]
[null,null,"Disciplina",null,"610.28"]
[null,null,"Soggetti",null,"Medical technology - Cost control"]
[{"$nulls":4},"Medical innovations - Cost control"]
[{"$nulls":4},"Medical care, Cost of"]
[{"$nulls":4},"Medical care - Cost control"]
[{"$nulls":4},"Health care reform"]
[{"$nulls":4},"Health insurance"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Includes index."]
[null,null,"Nota di contenuto",null,"Front matter -- Contents -- List of Illustrations -- Acknowledgments -- Introduction -- 1. Regulatory Access to the Market -- 2. Insurance Coverage and Reimbursement -- 3. Methods of Payment for Medical Technology -- 4. The Hospital as Purchaser -- 5. Organizational Capabilities for Technology Purchasing -- 6. The Patient as Purchaser -- 7. Implications for the Medical Technology Industry -- Notes -- Index"]
[null,null,null,"Sommario/riassunto","Innovation in medical technology generates a remarkable supply of new drugs, devices, and diagnostics that improve health, reduce risks, and extend life. But these technologies are too often used on the wrong patient, in the wrong setting, or at an unaffordable price. The only way to moderate the growth in health care costs without undermining the dynamic of medical innovation is to improve the process of assessing, pricing, prescribing, and using new technologies. Purchasing Medical Innovation analyzes the contemporary revolution in the purchasing of health care technology, with a focus on the roles of the Food and Drug Administration (FDA), Medicare and private health insurers, physicians and hospitals, and consumers themselves. The FDA is more thoroughly assessing product performance under real-world conditions as well as in laboratory settings, accelerating the path to market for "]
[{"$nulls":4},"breakthroughs while imposing use controls on risky products. Insurers are improving their criteria for coverage and designing payment methods that reward efficiency in the selection of new treatments. Hospitals are aligning adoption of complex supplies and equipment more closely with physicians' preferences for the best treatment for their patients. Consumers are becoming more engaged and financially accountable for their health care choices. This book describes both the strengths and deficiencies of the current system of purchasing and highlights opportunities for buyers, sellers, and users to help improve the value of medical technology: better outcomes at lower cost."]